This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Chouaid C, Vergnenègre A, Florentin V, Walzer S.Analysis of the costs of bevacizumab plus cisplatin and gemcitabine versus cetuximab plus vinorelbine and cisplatin in patients with advanced non-small cell lung cancer in France: results from a cost modelling study. 45th Annual Meeting of the American Society of Clinical Oncology: abstr. e17560, 29 May 2009. Available from: URL: http://www.abstract.asco.org
Heigener DF, Wiesner C, Aultman R.A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine versus cetuximab plus vinorelbine and cisplatin in patients with advanced or recurrent non-small cell lung cancer in Germany. 45th Annual Meeting of the American Society of Clinical Oncology: abstr. e17553, 29 May 2009. Available from: URL: http://www.abstract.asco.org
Rights and permissions
About this article
Cite this article
Bank on bevacizumab to save money in NSCLC. Pharmacoecon. Outcomes News 580, 6 (2009). https://doi.org/10.2165/00151234-200905800-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905800-00013